Five Prime(FPRX)

38.00 0.00 0.0%

今开:0.0昨收:38.0
最高:0.0 最低:0.0
涨停价:0.0跌停价:0.0
总市值:1.769737102E9

Five Prime的最新讨论

牛唐2021-04-13 21:53

$再鼎医药(ZLAB)$ 选药眼光真毒,$Five Prime(FPRX)$ 被收购,$Novocure(NVCR)$ 数据不错查看全文

7X24快讯2021-03-05 14:44

【安进19亿美元收购Five Prime Therapeutics】3月4日,安进(AMGN.O)宣布与Five Prime Therapeutics(FPRX.O)达成最终协议,将以38美元/股的价格全现金收购后者股票,对应股权总金额大约19亿美元。安进通过此次收购补强了自己的肿瘤创新药管线,包括获得了first in class的FGFR2b单抗bemarituzumab,...查看全文

牛唐2021-03-05 14:16

医药板块观察(2021.03.04)
1、$Five Prime(FPRX)$\$Pandion Therapeutics(PAND)相继被并购,可否燃起医药板块的热情?
2、$Talis Biomedical(TLIS)$ 新股破发,是否有配置价值?
$快手-W(01024)$查看全文

小小糖果2021-03-05 03:31

$Five Prime(FPRX)$ 今天唯一的安慰。查看全文

lisaff2021-03-05 01:15

$Five Prime(FPRX)$ 这么平的走势,怎么做到的呢查看全文

chuminhua2021-03-04 23:29

3月4日,安进(Amgen)宣布将以19亿美元收购Five Prime。Five Prime的核心产品为FGFR2b抗体bemarituzumab等。再鼎医药于2017年以500万美元预付款+3900万美元里程碑金额引进Bemarituzumab的大中华区权益。$安进(AMGN)$ $Five Prime(FPRX)$查看全文

产业链观察2021-03-04 22:35

药闻| 2021年3月4日,- $安进(AMGN)$$Five Prime(FPRX)$ (一家临床阶段的生物技术公司,专注于开发免疫肿瘤以及针对性癌症疗法),今天宣布了一项协议,安进公司将以每股38.00美元的现金价格收购Five Prime Therapeutics ,相当于约19亿美元的股权价值。
此次收购将Five Prime的创新产品线添...查看全文

Replix锐璞美股2021-03-04 22:03

$Five Prime(FPRX)$ 被收购!
Amgen (NASDAQ: AMGN) and Five Prime Therapeutics (NASDAQ: FPRX), a clinical-stage biotechnology company focused on developing immuno-oncology and targeted cancer therapies, today announced an agreement under which Amgen will acquire Five Prime ...查看全文

牛唐2020-12-08 22:00

$居里(CRIS)$$Five Prime(FPRX)$ 之后,第二个爆发的BVF概念股,下一个是谁?$蔚来(NIO)$查看全文

chuminhua2020-11-12 22:14

Five Prime Therapeutics日前宣布,其“first-in-class”靶向FGFR2b的单克隆抗体疗法bemarituzumab(FPA144),与化疗联用,在一线治疗晚期胃癌或胃食管连接部(GEJ)癌患者的2期临床试验中获得积极结果。这些患者的肿瘤为FGFR2b阳性,HER2阴性。新闻稿指出,这是首个表明针对FGFR2b的靶向治疗可能...查看全文

1 2 3 4 5

Five Prime的公告

$Five Prime(FPRX)$ 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] Filed: 2019-02-26 AccNo: 0001564590-19-004472 Size: 12 MB 网页链接

$Five Prime(FPRX)$ 美东时间 2019-02-26 盘后 披露财报,预期EPS -1.3 网页链接

$Five Prime(FPRX)$ SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals Filed: 2019-02-14 AccNo: 0000930413-19-000564 Size: 76 KB 网页链接

$Five Prime(FPRX)$ SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals Filed: 2019-02-14 AccNo: 0000921895-19-000475 Size: 209 KB 网页链接

$Five Prime(FPRX)$ SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals Filed: 2019-02-13 AccNo: 0000315066-19-001014 Size: 8 KB 网页链接

$Five Prime(FPRX)$ SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals Filed: 2019-02-13 AccNo: 0000093751-19-000075 Size: 8 KB 网页链接

$Five Prime(FPRX)$ SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals Filed: 2019-02-12 AccNo: 0000902219-19-000156 Size: 37 KB 网页链接

$Five Prime(FPRX)$ SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals Filed: 2019-02-11 AccNo: 0000932471-19-004485 Size: 34 KB 网页链接

$Five Prime(FPRX)$ SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals Filed: 2019-02-04 AccNo: 0000215457-19-004023 Size: 13 KB 网页链接

$Five Prime(FPRX)$ 8-K - Current report Filed: 2019-01-15 AccNo: 0001193125-19-009759 Size: 27 KBItem 8.01: Other EventsItem 9.01: Financial Statements and Exhibits 网页链接

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49